|drug2930||SARS-CoV-2 rS/Matrix-M1 Adjuvant Wiki||0.71|
|D045169||Severe Acute Respiratory Syndrome NIH||0.20|
|D018352||Coronavirus Infections NIH||0.16|
There is one clinical trial.
This is the first study of COVI-VAC in humans. The purpose of the study is to evaluate the safety and immune response of COVI-VAC (a live attenuated vaccine to prevent COVID-19) in healthy adults aged 18 to 30 years. Approximately 48 participants will be enrolled into 1 of 3 dose groups (low, medium, high). Within each of these dose groups, participants will be assigned randomly to receive either 2 doses of COVI-VAC 28 days apart, 2 doses of placebo (saline), or 1 dose of COVI-VAC and 1 dose of placebo. COVI-VAC or placebo is administered by drops into each nostril. Neither the participants nor the researchers will know whether COVI-VAC or placebo has been received. To assess the safety of the vaccine, each participant will record symptoms and oral temperature in a diary daily for 14 days after each dose. Safety laboratory tests, physical exams, ECGs, and a chest X-ray will also be performed, and peak expiratory flow and vital signs will be measured. Adverse events and medication use will be recorded. Blood samples and intranasal samples will be collected to assess the immune response from the vaccine.
Description: Percentage of subjects with reactogenicity eventsMeasure: Reactogenicity Time: 14 days after each dose
Description: Percentage of subjects with adverse eventsMeasure: Adverse events Time: Days 1 through 57
Description: Percentage of subjects with serious adverse eventsMeasure: Serious adverse events Time: Days 1-400
Description: IgG titre measured by ELISA in serum collected on Days 1, 15, 29, 43, 57, 120, 210, and 400Measure: IgG titre Time: Days 1, 15, 29, 43, 57, 120, 210, and 400
Description: Neutralising antibody level measured by microneutralisation assay in serumMeasure: Neutralizing antibody titre Time: Days 1, 15, 29, 43, 57, 120, 210, and 400
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports